Tom 3, Nr 1-2 (2023)
Artykuł przeglądowy
Opublikowany online: 2023-07-07
Wyświetlenia strony
308
Wyświetlenia/pobrania artykułu
18
Profilaktyka przeciwzakrzepowa u chorych leczonych inhibitorami kinazy tyrozynowej Brutona
Hematologia - Edukacja 2023;3(1-2):15-21.
Streszczenie
Wśród chorych leczonych inhibitorami kinazy tyrozynowej Brutona, takimi jak ibrutynib lub akalabrutynib, obserwuje się zwiększone ryzyko wystąpienia migotania przedsionków. Ryzyko tego powikłania, podobnie jak w populacji ogólnej, wzrasta z wiekiem chorych i współwystępowaniem chorób układu sercowo-naczyniowego. Ze względu na obserwowaną dysfunkcję płytek związaną z aktywnością ibrutynibu istotnym problemem klinicznym staje się profilaktyka przeciwzakrzepowa przeciwdziałająca udarowi mózgu. Obecność potencjalnych interakcji między ibrutynibem i doustnym lekiem przeciwzakrzepowym oraz dodatkowo zwiększone ryzyko krwawienia determinują określone wybory terapeutyczne, które opisano w artykule.
Słowa kluczowe: ibrutynibantykoagulantykrwawienieudarmigotanie przedsionków
Referencje
- Brown JR, Moslehi J, O'Brien S, et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017; 102(10): 1796–1805.
- Löpez-Fernández T, Canales M, Farmakis D, et al. Ibrutinib-associated atrial fibrillation: a practical approach. Ann Hematol Oncol. 2018; 5(4): 1203.
- Salem JE, Manouchehri A, Bretagne M, et al. Cardiovascular toxicities associated with ibrutinib. J Am Coll Cardiol. 2019; 74(13): 1667–1678.
- Brown JR, Byrd JC, Ghia P, et al. Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica. 2022; 107(6): 1335–1346.
- Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022; 43(41): 4229–4361.
- Shanafelt TD, Parikh SA, Noseworthy PA, et al. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2017; 58(7): 1630–1639.
- Hindricks G, Potpara T, Dagres N, et al. ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021; 42(5): 373–498.
- Lentz R, Feinglass J, Ma S, et al. Risk factors for the development of atrial fibrillation on ibrutinib treatment. Leuk Lymphoma. 2019; 60(6): 1447–1453.
- Mato AR, Clasen S, Pickens P, et al. Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia. Cancer Biol Ther. 2018; 19(1): 1–2.
- Menapace LA, McCrae KR, Khorana AA. Predictors of recurrent venous thromboembolism and bleeding on anticoagulation. Thromb Res. 2016; 140 Suppl 1: S93–S98.
- Angelini DE, Radivoyevitch T, McCrae KR, et al. Bleeding incidence and risk factors among cancer patients treated with anticoagulation. Am J Hematol. 2019; 94(7): 780–785.
- Pastori D, Marang A, Bisson A, et al. Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: A nationwide cohort study. Cancer. 2021; 127(12): 2122–2129.
- Boriani G, Lee G, Parrini I, et al. Council of Cardio-Oncology of the European Society of Cardiology. Anticoagulation in patients with atrial fibrillation and active cancer: an international survey on patient management. Eur J Prev Cardiol. 2021; 28(6): 611–621.
- D’Souza M, Carlson N, Fosbøl E, et al. CHA2DS2-VASC score and risk of thromboembolism and bleeding in patients with atrial fibrillation and recent cancer. Eur J Prev Cardiol. 2018; 25(6): 651–658.
- López-Fernández T, Martín-García A, Roldán Rabadán I, et al. Expert reviewers. Atrial fibrillation in active cancer patients: expert position paper and recommendations. Rev Esp Cardiol (Engl Ed). 2019; 72(9): 749–759.
- Delluc A, Wang TF, Yap ES, et al. Anticoagulation of cancer patients with non-valvular atrial fibrillation receiving chemotherapy: Guidance from the SSC of the ISTH. J Thromb Haemost. 2019; 17(8): 1247–1252.
- Falanga A, Leader A, Ambaglio C, et al. EHA Guidelines on management of antithrombotic treatments in thrombocytopenic patients with cancer. Hemasphere. 2022; 6(8): e750.
- Byrd JC, O'Brien S, James DF, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013; 369(1): 32–42.
- Byrd JC, Brown JR, O'Brien S, et al. RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014; 371(3): 213–223.
- Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015; 125(16): 2497–2506.
- Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015; 126(6): 739–745.
- Levade M, David E, Garcia C, et al. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood. 2014; 124(26): 3991–3995.
- Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015; 126(6): 739–745.
- Moreno C, Byrd JC, Hillmen P. Ibrutinib in previously treated chronic lymphocytic leukemia: updated efficacy and safety of the resonate study with up to four years of follow-up. Haematologica. 2017; 102(8): 311.
- Yun S, Vincelette ND, Acharya U, et al. Risk of atrial fibrillation and bleeding diathesis associated with ibrutinib treatment: a systematic review and pooled analysis of four randomized controlled trials. Clin Lymphoma Myeloma Leuk. 2017; 17(1): 31–37.e13.
- Gifkins DM, Matcho A, Yang H, et al. Incidence of major hemorrhage among CLL and MCL patients compared to the general elderly population: an analysis of the US SEER-Medicare Linked Database. Blood. 2015; 126(23): 3268–3268.
- Jones JA, Hillmen P, Coutre S, et al. Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. Br J Haematol. 2017; 178(2): 286–291.
- Brown JR, Moslehi J, O'Brien S, et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017; 102(10): 1796–1805.
- Gribben JG, Bosch F, Cymbalista F, et al. Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice. Br J Haematol. 2018; 180(5): 666–679.
- Mulligan SP, Ward CM, Whalley D, et al. Atrial fibrillation, anticoagulant stroke prophylaxis and bleeding risk with ibrutinib therapy for chronic lymphocytic leukaemia and lymphoproliferative disorders. Br J Haematol. 2016; 175(3): 359–364.
- Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013; 369(1): 32–42.
- Burger JA, Tedeschi A, Barr PM, et al. RESONATE-2 Investigators. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015; 373(25): 2425–2437.
- Wang ML, Lee H, Chuang H, et al. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol. 2016; 17(1): 48–56.
- Kirchhof P, Benussi S, Kotecha D, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37(38): 2893–2962.
- Chai KLi, Rowan G, Seymour JF, et al. Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib. Leuk Lymphoma. 2017; 58(12): 2811–2814.
- Boriani G, Corradini P, Cuneo A, et al. Practical management of ibrutinib in the real life: focus on atrial fibrillation and bleeding. Hematol Oncol. 2018; 36(4): 624–632.
- Lipsky AH, Lozier JN, Wiestner A, et al. Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 2015; 100(12): 1571–1578.
- Shatzel JJ, Olson SR, Tao DL, et al. Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. J Thromb Haemost. 2017; 15(5): 835–847.
